Israeli biotechnology company Thrombotech has obtained US Food and Drug Administration (FDA) approval for a Phase IIa clinical trial of its treatment for ischemic stroke by destroying blood clots. The trial will be conducted in the US and will test the safety of the drug, THR-18. The clinical trial was initiated at Hadassah Medical Center in Jerusalem and Sourasky Medical Center in Tel Aviv. The company is now waiting to receive regulatory permits for trials in Europe and India. View and Share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Drone Startups Team Up To Boost Destroyer Of Enemy Craft
March 26, 2024
Israeli Investment Management Company Raises $100M
March 26, 2024
Facebook comments